医療用医薬品 : タケキャブ (タケキャブ錠10mg 他) - KEGG
2024年12月18日 · 動物試験（ラット）において、最大臨床用量（40mg/日）におけるボノプラザンの曝露量（AUC）の約28倍を超える曝露量で、胎児体重及び胎盤重量の低値、外表異 …
Vonoprazan: First Global Approval | Drugs - Springer
2015年3月6日 · Vonoprazan (Takecab ®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related …
Vonoprazan: first global approval - PubMed
Vonoprazan (Takecab (®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The …
Takecab Tablets 20mg [agents for killing Helicobacter
Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, …
Takecab Tablets 20mg : Takeda Pharmaceutical Company …
“Takecab Tablets 20mg” is a prescription medicine (Rx) in Japan. 2. IMPORT (SUPPORTING) DOCUMENTS. Certificate of Origin (CoO), Patient Information Leaflet (PIL) and Summary of …
Takecab Tablets 20mg [agents for killing Helicobacter pylori]
In general, for adults, take 1 tablet (20 mg of vonoprazan) at a time, twice a day for 7 days. Take this medicine together with two antibacterial medicines. Strictly follow the instructions. If you …
New Drug Application for Oral Disintegrated Tablet Formulation …
2021年3月22日 · TAKECAB OD tablets are suitable for patients with impaired swallowing, including elderly patients, and the increase in treatment options can also be expected to …
New Drug Application Approval of TAKECAB® for the …
2014年12月26日 · TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P …
Takeda Obtains New Drug Application Approval for Helicobacter pylori ...
2016年2月26日 · Takeda has obtained New Drug Application approval in Japan for “VONOSAP ® pack 400” and “VONOSAP ® pack 800”, each being a triple-drug blister pack containing the …
Vonoprazan Fumarate - New Drug Approvals
2016年4月24日 · Vonoprazan (Takecab(®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related …